Crystalline isoxazole derivative and medical preparation thereof
AssigneeDainippon Sumitomo Pharma Co., Ltd.
InventorsYasushi Ochiai, Kazuhiko Tomomura, Hiroyuki Nishii
Life of this patent
Estimating the term…
Abstract
Crystalline 3-[(1S)-1-(2-fluorobiphenyl-4-yl)ethyl]-5-{[amino(morpholin-4-yl)methylene]amino}-isoxazole that exhibits the following angle of diffraction (2θ) and relative intensity in a powder X-ray diffraction pattern, is very easy to handle and stable in a process of its formulation into a pharmaceutical preparation. 1 2θ (°) Relative intensity (%) 6.1 100 14.1 55 16.0 74 18.5 36 20.0 43 25.4 39
Claims15
Crystalline 3-[(1S)-1-(2-fluorobiphenyl-4-yl)ethyl]-5-{[amino(morpholin-4-yl)methylene]amino}-isoxazole that exhibits the following angle of diffraction (2θ) and relative intensity in a powder X-ray diffraction pattern:
- 13 2θ (°) Relative intensity (%) 6.1 100 14.1 55 16.0 74 18.5 36 20.0 43 25.4 39
A process for producing crystalline 3-[(1S)-1-(2-fluorobiphenyl-4-yl)ethyl]-5-{[amino(morpholin-4-yl)methylene]amino}isoxazole by crystallizing 3-[(1S) -1-(2-fluorobiphenyl-4-yl)ethyl]-5-{[amino(morpholin-4-yl)methylene]amino}isoxazole from a mixed solvent of a hydrophilic solvent and water.
Dependencies are inferred from the claim text.